CooperVision Posts Strong Quarter as MyDay Portfolio Drives Global Growth

Premium daily lens range continues to outperform, with myopia management product MiSight gaining early traction

CooperCompanies has kicked off its 2026 fiscal year on a strong footing, reporting first quarter revenue of US$1.024 billion, a 6% year-on-year increase, with its CooperVision contact lens division leading the charge on the back of sustained demand for premium daily lenses.

For eyecare practitioners across Australia who stock and fit Cooper's lens portfolio, the results signal continued investment confidence in the product lines they prescribe most, particularly the MyDay family and the MyDay MiSight myopia management lens.

CooperVision generated US$695.1 million in revenue for the quarter ended 31 January 2026, up 8% reported and 3% organically. Toric and multifocal lenses were the clear growth engine, rising 10% on reported figures and 6% organically to US$351.2 million, a result that reflects growing practitioner confidence in fitting premium modalities.

Geographically, the Americas led with 6% organic growth, while EMEA posted 4%. Asia Pacific, the region most relevant to Australian market dynamics, was the one soft spot, declining 4% in both reported and constant currency terms, suggesting continued competitive pressure in that corridor.

Chief Executive Al White pointed specifically to the MyDay portfolio and early momentum from MyDay MiSight as key revenue contributors. "Momentum is building from product launches including early traction from MyDay MiSight," White said, a signal that the company's myopia management ambitions are beginning to convert commercially following the product's rollout.

CooperSurgical, which serves the women's health and fertility sector, contributed US$329.0 million, up 3% reported and 2% organically. Its fertility segment grew at a faster clip of 3% organically, while the office and surgical category edged up 2%.

Non-GAAP operating margin expanded 180 basis points year-on-year to 27%, with management crediting a reorganisation completed last year and improved leverage from IT system rollouts. GAAP operating margin improved from 19% to 21%.

One notable caveat: gross margin on a non-GAAP basis slipped 60 basis points to 68%. The company disclosed that tariffs were a contributing factor, noting that excluding their impact, gross margin would have been flat year-on-year, a point worth watching as trade policy uncertainty continues globally.

Diluted GAAP earnings per share came in at US$0.66, up 27%, while non-GAAP diluted EPS rose 20% to US$1.10.

Buoyed by the result, CooperCompanies lifted its full-year fiscal 2026 guidance. The company now expects total revenue of US$4.306–$4.346 billion, with CooperVision projected at US$2.906–$2.932 billion and CooperSurgical at US$1.400–$1.413 billion. Organic growth guidance of 4.5%–5.5% for CVI and 4.0%–5.0% for CSI was maintained.

Non-GAAP diluted EPS guidance was raised to US$4.58–$4.66, and free cash flow guidance lifted to US$600–$625 million for the year. The company reiterated its longer-term target of generating more than US$2.2 billion in cumulative free cash flow between 2026 and 2028.

For Australian optometrists and optical dispensers, the results reinforce Cooper's ongoing commitment to its premium daily and specialty lens segments, the categories that tend to generate the strongest chair time value and patient retention outcomes. The early traction cited for MyDay MiSight will be of particular interest given the growing clinical focus on myopia management in paediatric patients across the Asia Pacific region.

The soft Asia Pacific numbers are worth monitoring, though they reflect broader currency and market dynamics rather than any product-specific weakness.